Castle Biosciences/CSTL

$24.51

-0.08%
-
1D1W1MYTD1YMAX

About Castle Biosciences

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Its portfolio consists of tests for skin cancers, uveal melanoma, Barretts esophagus and mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, and DecisionDx-UM, IDgenetix. DecisionDx-Melanoma is a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM), a deadly skin cancer. MyPath Melanoma is GEP test offering for patients with difficult-to-diagnose melanocytic lesions. IDgenetix is pharmacogenomics (PGx) test that helps to guide optimal drug treatment for patients diagnosed with major depressive disorder, bipolar disorder, and other.

Ticker

CSTL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Derek Maetzold

Employees

610

Headquarters

Friendswood, United States

CSTL Metrics

BasicAdvanced
$673M
Market cap
-
P/E ratio
-$1.15
EPS
0.96
Beta
-
Dividend rate
$673M
0.95537
$26.70
$9.26
261K
9.255
9.016
2.489
2.489
-6.96%
-7.82%
-7.48%
2.683
1.67
2.341
64.71%
57.68%
51.95%

What the Analysts think about CSTL

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 9 analysts.
40.07% upside
High $40.00
Low $28.00
$24.51
Current price
$34.33
Average price target

CSTL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-3.42% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$73M
10.29%
Net income
-$2.5M
-0%
Profit margin
-3.42%
-9.52%

CSTL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 72.87%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.26
-$0.10
-$0.09
-
Expected
-$0.92
-$0.76
-$0.54
-$0.33
-$0.29
Surprise
-23.5%
-65.96%
-81.35%
-72.87%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Castle Biosciences stock?

Castle Biosciences (CSTL) has a market cap of $673M as of May 29, 2024.

What is the P/E ratio for Castle Biosciences stock?

The price to earnings (P/E) ratio for Castle Biosciences (CSTL) stock is 0 as of May 29, 2024.

Does Castle Biosciences stock pay dividends?

No, Castle Biosciences (CSTL) stock does not pay dividends to its shareholders as of May 29, 2024.

When is the next Castle Biosciences dividend payment date?

Castle Biosciences (CSTL) stock does not pay dividends to its shareholders.

What is the beta indicator for Castle Biosciences?

Castle Biosciences (CSTL) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Castle Biosciences stock price target?

The target price for Castle Biosciences (CSTL) stock is $34.33, which is 40.07% above the current price of $24.51. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Castle Biosciences stock

Buy or sell Castle Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing